Humanigen WKN: A2QEQW ISIN: US4448632038 Kürzel: HGEN Forum: Aktien Thema: Hauptdiskussion

Ich hatte Donnerstag 24.000 Stk gekauft

Heute wieder aktualisiert... Hat jemand schon ge- oder verkauft?

LS hat keinen Kurs mehr

Nö, läuft jetzt aber nicht mehr an der Nasdaq sondern über Pink.

Gibt es eine neue wkn?

Ende am Gelände…

All In

Nur noch OTC Markt

Delisting kommt

Kommt hier noch was?

Was ist los?

😁😀👍

🤔

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durable CMML is a rare, aggressive cancer; approximately 20% of patients survive three years from diagnosis No new CMML medications with novel mechanisms of action have been approved in over 30 years and hypomethylating agents, such as azacitidine alone, are currently considered "standard of care"

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

On April 18, 2023, Humanigen, Inc. (the “Company”) was notified that it had been granted an extension until August 21, 2023 to demonstrate compliance with all applicable requirements for listing of the Company’s common stock on Nasdaq by the Nasdaq Hearings Panel (the “Panel”), subject to the Company’s compliance with the Panel’s requirements for periodic updates relating to the status of the Company’s progress against achievement of the compliance plan presented at the April 6, 2023 hearing with the Panel. There can be no assurance that the Company will be successful in its execution of its compliance plan or otherwise regain compliance with the applicable Nasdaq listing requirements within the extended compliance period.